Impact of fluconazole administration on outcomes in critically ill patients

被引:5
|
作者
Garrelts, JC
Schroeder, TR
Harrison, PB
机构
[1] Wesley Med Ctr, Clin Pharm Serv & Res, Wichita, KS 67214 USA
[2] Wesley Med Ctr, Infect Dis, Wichita, KS 67214 USA
[3] Wesley Med Ctr, Trauma Program, Wichita, KS 67214 USA
关键词
fluconazole; outcomes; trauma;
D O I
10.1345/aph.1D441
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND: Serious infections caused by Candida spp. are an increasingly important cause of morbidity and mortality in critically ill patients. it is unclear which patients will benefit from therapy and at what point to institute treatment. OBJECTIVE: To evaluate the impact of administration of fluconazole therapy in critically ill trauma patients on mortality, length of hospital stay, incidence of deep-seated fungal infection, and positive fungal cultures from any site. METHODS: We conducted a retrospective, matched case-control study of 116 critically ill surgical trauma patients who did or did not receive fluconazole. Patients were followed until hospital discharge or death. A consecutive sample of 58 patients who received fluconazole was selected. A parallel group of patients was evaluated, from which 58 were matched with fluconazole-treated patients based on age (+/-5 y), gender, and APACHE II score (+/- 3). RESULTS: The groups of patients were well matched, with the exception of central venous catheter placement and broad-spectrum antibiotic use. We found no difference between groups in hospital mortality (21% vs 26%; p = 0.661) or incidence of deep-seated fungal infection (0% vs 2%; p = NS). However, patients receiving fluconazole had a significantly longer stay in both the intensive care unit (ICU) (18 +/- 13 vs 7 +/- 11 days; p < 0.001) and hospital (25 +/- 15 vs 9 +/- 11 days; p < 0.001). Fluconazole patients were significantly more likely to have Candida cultured from sites associated with colonization (43% vs 2%; p < 0.001), possibly explaining why they received fluconazole. CONCLUSIONS: We were unable to detect a benefit from use of fluconazole in our surgical trauma patient population. Isolation of Candida from the mouth or throat alone, in the absence of correlating clinical signs of infection, should not lead to initiation of fluconazole therapy. Fluconazole use should be reserved for carefully selected patients in the trauma ICU setting.
引用
收藏
页码:1588 / 1592
页数:5
相关论文
共 50 条
  • [31] Impact of administration of vancomycin or linezolid to critically ill patients with impaired renal function
    Rodriguez Colomo, O.
    Alvarez Lerma, F.
    Gonzalez Perez, M. I.
    Sirvent, J-M
    Garcia Simon, M.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2011, 30 (05) : 635 - 643
  • [32] Possible association between fluconazole administration and acute hyperkalemia in a critically ill cyanotic infant
    Elkiran, Ozlem
    Karakurt, Cemsit
    Kocak, Gulendam
    Tabel, Yilmaz
    Gungor, Serdal
    ARCHIVES OF MEDICAL SCIENCE, 2015, 11 (01) : 235 - 236
  • [33] Pathophysiology of fluid administration in critically ill patients
    Messina, Antonio
    Bakker, Jan
    Chew, Michelle
    De Backer, Daniel
    Hamzaoui, Olfa
    Hernandez, Glenn
    Myatra, Sheila Nainan
    Monnet, Xavier
    Ostermann, Marlies
    Pinsky, Michael
    Teboul, Jean-Louis
    Cecconi, Maurizio
    INTENSIVE CARE MEDICINE EXPERIMENTAL, 2022, 10 (01)
  • [34] Human albumin administration in critically ill patients
    Ferguson, ND
    Stewart, TE
    Etchells, EE
    INTENSIVE CARE MEDICINE, 1999, 25 (03) : 323 - 325
  • [35] Pathophysiology of fluid administration in critically ill patients
    Antonio Messina
    Jan Bakker
    Michelle Chew
    Daniel De Backer
    Olfa Hamzaoui
    Glenn Hernandez
    Sheila Nainan Myatra
    Xavier Monnet
    Marlies Ostermann
    Michael Pinsky
    Jean-Louis Teboul
    Maurizio Cecconi
    Intensive Care Medicine Experimental, 10
  • [36] Human albumin administration in critically ill patients
    N. D. Ferguson
    T. E. Stewart
    E. E. Etchells
    Intensive Care Medicine, 1999, 25 : 323 - 325
  • [37] Fluconazole prophylaxis for critically ill patients at high risk for Candida infection
    Garbino, J
    CLINICAL INFECTIOUS DISEASES, 2005, 41 (11) : 1690 - 1691
  • [38] Suboptimal exposure to fluconazole in critically ill patients: Pharmacokinetic analysis and determinants
    Bienvenu, A. L.
    Pradat, P.
    Matusik, E.
    Piriou, V.
    Rimmele, T.
    Parant, F.
    Tod, M.
    Leboucher, G.
    Goutelle, S.
    INFECTIOUS DISEASES NOW, 2023, 53 (02):
  • [39] Fluconazole Underexposure in Critically Ill Patients: a Matter of Using the Right Targets?
    Van Daele, Ruth
    Debaveye, Yves
    Lagrou, Katrien
    Spriet, Isabel
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (06)
  • [40] Association between furosemide administration and outcomes in critically ill patients with acute kidney injury
    Zhao, Guang-ju
    Xu, Chang
    Ying, Jian-chao
    Lu, Wen-biao
    Hong, Guang-liang
    Li, Meng-fang
    Wu, Bing
    Yao, Yong-ming
    Lu, Zhong-qiu
    CRITICAL CARE, 2020, 24 (01):